Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001636282-25-000064
Filing Date
2025-06-02
Accepted
2025-06-02 16:34:34
Documents
1
Period of Report
2025-05-29

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1748896459.html 4  
1 FORM 4 wk-form4_1748896459.xml 4 4014
  Complete submission text file 0001636282-25-000064.txt   5622
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Spyre Therapeutics, Inc. (Issuer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address BLUEPRINT MEDICINES CORP. 215 FIRST STREET, SUITE 340/350 CAMBRIDGE MA 02142
Business Address
Albers Jeffrey W. (Reporting) CIK: 0001638474 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37722 | Film No.: 251015558